

Appl. No. 10/632,949
Reply to Office Action mailed August 2, 2006

Amendments to the Claims:


This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1. (canceled)

Claim 2. (canceled)


Claim 3. (currently amended) [[The]] An isolated peptide according [[to]] claim [[2]] or a salt thereof, wherein the peptide has the following formula (I):



Appl. No. 10/632,949
Reply to Office Action mailed August 2, 2006

Claim 4. (canceled)


Claim 5. (withdrawn - currently amended) [[The]] An
isolated peptide according [[to]] claim [[4]] or a salt thereof
, wherein the peptide has the following formula (II):



Claim 6. (canceled)

Claim 7. (withdrawn - currently amended) [[The]] An isolated
peptide according [[to]] claim [[6]] or a salt thereof, wherein
the peptide has the following formula (III):

Appl. No. 10/632,949
 Reply to Office Action mailed August 2, 2006




Claim 8. (canceled)

Claim 9. (canceled)

Claim 10. (currently amended) [[The]] An isolated lower-alkylated derivative according [[to]] claim [[9]] of a peptide or a salt thereof, wherein said derivative has the following formula
(VI) :

Appl. No. 10/632,949
 Reply to Office Action mailed August 2, 2006




, wherein R is a methyl group or a salt thereof.

Claim 11. (canceled)

Claim 12. (canceled)

Claim 13. (currently amended) [[The]] An isolated peptide according [[to]] claim [[12]] or a salt thereof, wherein the peptide has the following formula (IV) :


Appl. No. 10/632,949
 Reply to Office Action mailed August 2, 2006



Claim 14. (canceled)

Claim 15. (canceled)

Claim 16. (currently amended) [[The]] An isolated peptide according [[to]] claim [[15]] or a salt thereof, wherein the peptide has the following formula (V) :



Appl. No. 10/632,949
Reply to Office Action mailed August 2, 2006

Claims 17 to 23. (canceled)

Claim 24. (new) The peptide according to claim 3, wherein the peptide is isolated and purified from a culture of *Pseudomonas* sp. RtIB026 deposited under accession number FERM BP-7436.

Claim 25. (new) A method of preparing the peptide according to claim 3, comprising:

culturing *Pseudomonas* sp. RtIB026 deposited under accession number FERM BP-7436,

obtaining a culture product of the microorganism; and recovering the peptide according to claim 3 from the culture product.

Claim 26. (new) An antiviral composition comprising a pharmaceutically effective amount of the peptide according to claim 3, in combination with a pharmaceutically acceptable carrier.

Appl. No. 10/632,949
Reply to Office Action mailed August 2, 2006

Claim 27. (new) A method of preventing a subject from infection with a virus and/or treating a subject suffering from infection with a virus, comprising administering to the subject in need thereof a pharmaceutically effective amount of the peptide according to claim 3 as an effective ingredient.

Claim 28. (new) The peptide according to claim 13, wherein the peptide is isolated and purified from a culture of *Pseudomonas* sp. RtIB026 deposited under accession number FERM BP-7436.

Claim 29. (new) A method of preparing the peptide according to claim 13, comprising:

culturing *Pseudomonas* sp. RtIB026 deposited under accession number FERM BP-7436,
obtaining a culture product of the microorganism; and
recovering the peptide according to claim 13 from the culture product.

Claim 30. (new) An antiviral composition comprising a pharmaceutically effective amount of the peptide according to

Appl. No. 10/632,949
Reply to Office Action mailed August 2, 2006

claim 13, in combination with a pharmaceutically acceptable carrier.

Claim 31. (new) A method of preventing a subject from infection with a virus and/or treating a subject suffering from infection with a virus, comprising administering to the subject in need thereof a pharmaceutically effective amount of the peptide according to claim 13 as an effective ingredient.

Claim 32. (new) The peptide according to claim 16, wherein the peptide is isolated and purified from a culture of *Pseudomonas* sp. RtIB026 deposited under accession number FERM BP-7436.

Claim 33. (new) A method of preparing the peptide according to claim 16, comprising:

culturing *Pseudomonas* sp. RtIB026 deposited under accession number FERM BP-7436,

obtaining a culture product of the microorganism; and recovering the peptide according to claim 16 from the culture product.

Appl. No. 10/632,949
Reply to Office Action mailed August 2, 2006

Claim 34. (new) An antiviral composition comprising a pharmaceutically effective amount of the peptide according to claim 16, in combination with a pharmaceutically acceptable carrier.

Claim 35. (new) A method of preventing a subject from infection with a virus and/or treating a subject suffering from infection with a virus, comprising administering to the subject in need thereof a pharmaceutically effective amount of the peptide according to claim 16 as an effective ingredient.

Claim 36. (new) An antiviral composition comprising a pharmaceutically effective amount of the peptide according to claim 5, in combination with a pharmaceutically acceptable carrier.

Claim 37. (new) A method of preventing a subject from infection with a virus and/or treating a subject suffering from infection with a virus, comprising administering to the subject in need thereof a pharmaceutically effective amount of the peptide according to claim 5 as an effective ingredient.

Appl. No. 10/632,949
Reply to Office Action mailed August 2, 2006

Claim 38. (new) An antiviral composition comprising a pharmaceutically effective amount of the peptide according to claim 7, in combination with a pharmaceutically acceptable carrier.

Claim 39. (new) A method of preventing a subject from infection with a virus and/or treating a subject suffering from infection with a virus, comprising administering to the subject in need thereof a pharmaceutically effective amount of the peptide according to claim 7 as an effective ingredient.

Claim 40. (new) An antiviral composition comprising a pharmaceutically effective amount of the peptide according to claim 10, in combination with a pharmaceutically acceptable carrier.

Claim 41. (new) A method of preventing a subject from infection with a virus and/or treating a subject suffering from infection with a virus, comprising administering to the subject in need thereof a pharmaceutically effective amount of the peptide according to claim 10 as an effective ingredient.